In my opinion, this is a company with products that are for the most part ahead of its markets. Without China approval this company will continue to languish and bleed cash until stem cell treatments become prevalent or gets bought out at a low price (most likely the latter). Without China approval it will need to continue to focus on cash preservation and lowering costs. With China approval it has a much better chance of surviving until its markets catch up with its products. China I think will be more aggressive in the stem cell space as opposed to others.